Parcourir par sujet "chelation therapy"

Voici les éléments 1-3 de 3

Patients with haemoglobinopathies and chronic hepatitis C: A real difficult to treat population in 2016?

Zachou K., Arvaniti P., Gatselis N.K., Azariadis K., Papadamou G., Rigopoulou E., Dalekos G.N. (2017)

Background & objectives: In the past, patients with haemoglobinopathies were at high risk of acquiring hepatitis C virus (HCV) due to multiple transfusions before HCV screening. In these patients, the coexistence of ...
Pulmonary function abnormalities in young adults with thalassemia major

Gourgoullanis, K. I.; Gouslou, A.; Papaioannou, G.; Halkias, C.; Stathakis, N.; Molyvdas, P. A. (1997)

Thalassemia seems to be the most common genetic disorder. The pathophysiologic mechanisms for lung impairment is not clear. Lung function tests in children showed small airway obstruction and restrictive lung changes. ...
Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease

Sinakos E., Kountouras D., Koskinas J., Zachou K., Karatapanis S., Triantos C., Vassiliadis T., Goulis I., Kourakli A., Vlachaki E., Toli B., Tampaki M., Arvaniti P., Tsiaoussis G., Bellou A., Kattamis A., Maragkos K., Petropoulou F., Dalekos G.N., Akriviadis E., Papatheodoridis G.V. (2017)

Interferon-based regimens for chronic hepatitis C (CHC) were often deferred in patients with β-thalasaemia major (β-TM) due to poor efficacy and tolerance. Current guidelines recommend direct-acting antivirals (DAAs) for ...